Trial Profile

Optimal strategy in K-ras wild type metastatic colorectal cancer patients: cetuximab plus FOLFIRI followed by FOLFOX+/- cetuximab (GOIM multicenter program)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms CAPRI-GOIM

Most Recent Events

12 Sep 2017 Mature survival data (cut off date: April 30, 2017; n=98) presented at the 42nd European Society for Medical Oncology Congress
12 Sep 2017 Results of liquid biopsy analysis (n=96) presented at the 42nd European Society for Medical Oncology Congress
12 Sep 2017 Results assessing Eph A2 expression is a predictive biomarker of treatment efficacy, presented at the 42nd European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com